Boston Scientific Corporation (ETR:BSX)
Germany
· Delayed Price · Currency is EUR | Market Cap | 124.27B |
| Revenue (ttm) | 16.49B |
| Net Income (ttm) | 2.38B |
| Shares Out | n/a |
| EPS (ttm) | 1.59 |
| PE Ratio | 52.24 |
| Forward PE | 29.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 292 |
| Open | 83.40 |
| Previous Close | 84.00 |
| Day's Range | 83.40 - 83.40 |
| 52-Week Range | 75.20 - 104.00 |
| Beta | n/a |
| RSI | 42.65 |
| Earnings Date | Feb 5, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews
If You Invested $1000 In Boston Scientific Stock 5 Years Ago, You Would Have This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 5 years by 10.84% on an annualized basis producing an average annual return of 23.89%. Currently, Boston Scientific has a marke...
M&A Strategy Strengthens Boston Scientific's Growth Prospects
BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.
Brianne Gardner's Top Picks: Constellation Energy, Microsoft & Boston Scientific
Brianne Gardner, portfolio manager & senior wealth manager at Velocity Investment Partners, Raymond James, shares her top stock picks to watch in the market.
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts...
Boston Scientific's Margins Strengthen in Q3: What's Driving It?
BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.
BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?
Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.
BSX Quantitative Stock Analysis - Peter Lynch
Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/E/Growth Investor model based on the published strategy ...
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Boston Scientific (BSX) Down 5.7% Since Last Earnings Report: Can It Rebound?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific (BSX) Announces 2026 Compensation Plans to Drive Performance and Shareholder Value
Boston Scientific (BSX) Announces 2026 Compensation Plans to Drive Performance and Shareholder Value
BSX's Neuromodulation Prospect Looks Strong: What's Behind It?
Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.
$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 7.62% on an annualized basis producing an average annual return of 19.65%. Currently, Boston Scientific has a marke...
Boston Scientific Corporation (BSX) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion
Boston Scientific, Insulet, BioLife Solutions and Allurion push ahead with innovation and efficiency as the Medical Products industry faces pressure.
Boston Scientific Up 7% in a Month: How Should You Play the Stock?
BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness...
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.
What's Behind Boston Scientific's Optimism for Urology Growth?
BSX sees stronger 2026 prospects for Urology, powered by Axonics integration, innovation and global Stone Management momentum.
A Look Into Boston Scientific Inc's Price Over Earnings
In the current session, the stock is trading at $99.67, after a 0.62% increase. Over the past month, Boston Scientific Inc. (NYSE: BSX) stock increased by 3.82% , and in the past year, by 11.95% . Wi...
Insider Sell: Ellen Zane Sells Shares of Boston Scientific Corp (BSX)
Insider Sell: Ellen Zane Sells Shares of Boston Scientific Corp (BSX)
Elutia Inc Reports Q3 2025 Revenue of $3. ...
Elutia Inc Reports Q3 2025 Revenue of $3.3 Million, Missing Estimates; Strategic Sale to Boston Scientific Completed
Artisan Global Opportunities Fund Q3 2025 Portfolio Update
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campa...